New Ebola Mutation Identified By Chinese Researchers Could Sharpen Outbreak Surveillance

Chinese researchers have identified a critical mutation in the Ebola virus that significantly increased its infectivity during a major outbreak, offering important insights for epidemic surveillance, drug development, and outbreak preparedness.

The findings, published in the journal Cell, are based on an analysis of the Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo (DRC) between 2018 and 2020. This outbreak was the second-largest Ebola epidemic on record, resulting in more than 3,000 infections and over 2,000 deaths.

The research examined whether viral evolution—beyond local healthcare system challenges—played a role in prolonging the outbreak. To investigate this, scientists analysed 480 complete Ebola virus genomes collected during the epidemic. The analysis revealed the emergence of a viral variant carrying a specific mutation in the Ebola virus glycoprotein, known as GP-V75A.

This variant appeared early in the DRC outbreak and rapidly replaced the original circulating strain. Its increasing prevalence closely tracked the rise in Ebola case numbers, suggesting that the mutation conferred a transmission advantage.

Further laboratory experiments using multiple biological models confirmed the mutation’s functional impact. The GP-V75A mutation significantly enhanced the virus’s ability to infect various types of host cells as well as mice, demonstrating increased infectivity.

The study also highlighted a potential clinical concern. The GP-V75A mutation was found to reduce the effectiveness of certain existing therapeutic antibodies and small-molecule entry inhibitors, raising concerns about possible drug resistance during future outbreaks.

Overall, the findings underscore the critical importance of real-time genomic surveillance and evolutionary analysis during major infectious disease outbreaks. Continuous monitoring of viral mutations can help detect changes in transmission risk, assess the ongoing effectiveness of vaccines and treatments, and guide timely adjustments to public health control strategies.

Also Read